This company listing is no longer active
Mendus Résultats passés
Passé contrôle des critères 0/6
Mendus's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 2.6% annually. Revenues have been declining at an average rate of 3.5% per year.
Informations clés
-12.1%
Taux de croissance des bénéfices
29.7%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 0.7% |
| Taux de croissance des recettes | -3.5% |
| Rendement des fonds propres | -29.0% |
| Marge nette | -10,319.1% |
| Prochaine mise à jour des résultats | 29 Aug 2023 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Ventilation des recettes et des dépenses
Comment Mendus gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 23 | 1 | -141 | 50 | 88 |
| 31 Dec 22 | 3 | -139 | 49 | 87 |
| 30 Sep 22 | 2 | -128 | 47 | 79 |
| 30 Jun 22 | 2 | -117 | 41 | 72 |
| 31 Mar 22 | 2 | -119 | 41 | 75 |
| 31 Dec 21 | 0 | -133 | 43 | 86 |
| 30 Sep 21 | 0 | -148 | 41 | 83 |
| 30 Jun 21 | 0 | -138 | 34 | 80 |
| 31 Mar 21 | 0 | -119 | 27 | 68 |
| 31 Dec 20 | 0 | -89 | 18 | 48 |
| 30 Sep 20 | 16 | 3 | 2 | 7 |
| 30 Jun 20 | 16 | -11 | 4 | 19 |
| 31 Mar 20 | 17 | -31 | 9 | 35 |
| 31 Dec 19 | 17 | -48 | 13 | 49 |
| 30 Sep 19 | 0 | -118 | 26 | 91 |
| 30 Jun 19 | 0 | -112 | 27 | 85 |
| 31 Mar 19 | 0 | -98 | 26 | 72 |
| 31 Dec 18 | 0 | -98 | 26 | 71 |
| 30 Sep 18 | 0 | -90 | 25 | 66 |
| 30 Jun 18 | 0 | -89 | 23 | 65 |
| 31 Mar 18 | 0 | -88 | 22 | 66 |
| 31 Dec 17 | 0 | -80 | 23 | 58 |
| 30 Sep 17 | 0 | -86 | 41 | 45 |
| 30 Jun 17 | 0 | -77 | 48 | 28 |
| 31 Mar 17 | 0 | -72 | 58 | 14 |
| 31 Dec 16 | 0 | -61 | 61 | 0 |
| 30 Sep 16 | 0 | -48 | 47 | 0 |
| 30 Jun 16 | 0 | -44 | 43 | 0 |
| 31 Mar 16 | 0 | -37 | 37 | 0 |
| 31 Dec 15 | 0 | -38 | 38 | 0 |
| 30 Sep 15 | 0 | -37 | 38 | 0 |
| 30 Jun 15 | 0 | -36 | 36 | 0 |
| 31 Mar 15 | 0 | -33 | 34 | 0 |
| 31 Dec 14 | 0 | -28 | 28 | 0 |
| 30 Sep 14 | 0 | -21 | 22 | 0 |
| 30 Jun 14 | 0 | -16 | 17 | 0 |
| 31 Mar 14 | 0 | -13 | 14 | 0 |
| 31 Dec 13 | 0 | -10 | 11 | 0 |
| 30 Sep 13 | 0 | -8 | 8 | 0 |
| 30 Jun 13 | 0 | -7 | 7 | 0 |
| 31 Mar 13 | 0 | -6 | 5 | 0 |
| 31 Dec 12 | 0 | -5 | 3 | 0 |
| 30 Sep 12 | 0 | -5 | 2 | 0 |
Des revenus de qualité: IMMU BTU is currently unprofitable.
Augmentation de la marge bénéficiaire: IMMU BTU is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: IMMU BTU is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
Accélération de la croissance: Unable to compare IMMU BTU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: IMMU BTU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Rendement des fonds propres
ROE élevé: IMMU BTU has a negative Return on Equity (-28.98%), as it is currently unprofitable.